Recent advances in the application of polymeric nanoparticles to the pulmonary delivery of mRNA DOI Creative Commons

Peyton M. Panovich,

A. Ganesan,

Amogh R. Angadi

et al.

Nanomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 17

Published: May 30, 2025

Messenger RNA (mRNA)-based therapeutics offer the potential to treat a variety of pulmonary disorders that arise due genetics, infectious diseases, and chronic respiratory conditions. However, various physiological barriers in lungs, such as mucociliary clearance, macrophage phagocytosis, lung surfactant interference, present challenges for efficient mRNA delivery. Polymeric nanoparticles (NPs) have emerged therapeutic platform delivering their stability, tunability, controlled release properties, making them suitable potentially ideal encapsulating protecting molecules delivery vivo. Continued advances polymer NP design improved mucus penetration cellular uptake upon delivery; further, administration via local systemic routes enable modulation biodistribution. These advancements benefit treatment range including viral infections, cystic fibrosis (CF), asthma, cancer, by facilitating immune genetic therapy In this review, we explore how polymeric NPs address disease-specific requirements expand mRNAs lung.

Language: Английский

Development of a mucoadhesive drug delivery system and its interaction with gastric cells DOI Creative Commons
Ahmet Baki Sahin, Serdar Karakurt, Deniz Bilecen

et al.

Beilstein Journal of Nanotechnology, Journal Year: 2025, Volume and Issue: 16, P. 371 - 384

Published: March 13, 2025

Drugs that are designed for local treatment of gastric diseases require increased residence time prolonged action and efficacy. In this study, we report a mucoadhesive drug delivery system was developed to fulfill these requirements. Alginate nanoparticles were synthesized by water-in-oil emulsification followed external gelation then coated with the polymer Eudragit RS100. The formulated had mean size 219 nm positive charge. A peptide, as model drug, loaded onto an encapsulation efficiency 58%. release from pH-independent lasted 7 days. periodic acid–Schiff stain assay indicated 69% mucin interaction nanoparticles, which also capable diffusion through artificial mucus. not toxic epithelial cells can be internalized within 4 h. adsorption mucus-secreting found correlated cell number. in study is intended active therapeutic agents has potential used alternative strategy related diseases.

Language: Английский

Citations

0
The mucosal protein corona in local nanoparticle drug delivery DOI

A. Stern,

A. Petersen, Hannah C. Zierden

et al.

Published: March 1, 2025

Citations

0
Recent advances in the application of polymeric nanoparticles to the pulmonary delivery of mRNA DOI Creative Commons

Peyton M. Panovich,

A. Ganesan,

Amogh R. Angadi

et al.

Nanomedicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 17

Published: May 30, 2025

Messenger RNA (mRNA)-based therapeutics offer the potential to treat a variety of pulmonary disorders that arise due genetics, infectious diseases, and chronic respiratory conditions. However, various physiological barriers in lungs, such as mucociliary clearance, macrophage phagocytosis, lung surfactant interference, present challenges for efficient mRNA delivery. Polymeric nanoparticles (NPs) have emerged therapeutic platform delivering their stability, tunability, controlled release properties, making them suitable potentially ideal encapsulating protecting molecules delivery vivo. Continued advances polymer NP design improved mucus penetration cellular uptake upon delivery; further, administration via local systemic routes enable modulation biodistribution. These advancements benefit treatment range including viral infections, cystic fibrosis (CF), asthma, cancer, by facilitating immune genetic therapy In this review, we explore how polymeric NPs address disease-specific requirements expand mRNAs lung.

Language: Английский

Citations

0